相关实验视频
Updated: Jun 27, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
通过2'-O-甲基酸修饰的固体阻断抗感官寡核酸来抑制生存蛋白
Yalin Li1, Suxiang Chen2,3, Kamal Rahimizadeh2,3
1School of Food and Biological Engineering, Henan University of Animal Husbandry and Economy Zhengzhou 450018 China.
开发了针对瘤基因BIRC5的绝缘阻断性反感性寡核酸 (ASO). ASO-7有效抑制了BIRC5mRNA和幸存蛋白质的产生,显示了癌症治疗研究和开发的潜力.
科学领域:
- 橄核酸的治疗药物
- 癌症生物学 癌症生物学
- 分子瘤学分子瘤学
背景情况:
- 反感性寡核酸 (ASOs) 是各种疾病的已确立治疗方法,有十种已批准的药物.
- 目前的ASO疗法没有针对癌症.
- BIRC5是一种经过验证的瘤基因,也是潜在的治疗点.
研究的目的:
- 开发针对瘤基因BIRC5.5的固体阻断性反感 oligonucleotides (ASOs).
- 评估新型ASO在抑制BIRC5表达中的有效性.
- 评估ASO-7作为BIRC5抑制剂在癌症治疗中的潜力.
主要方法:
- 在HepG2细胞中选七个针对BIRC5外子-2的ASO.
- 剂量反应测试以确定最佳的ASO度.
- 西方斑点分析以确认蛋白质水平的抑制.
主要成果:
- 确定了两个主要的ASO候选者,ASO-2和ASO-7,用于减少BIRC5mRNA.
- 无论是ASO-2还是ASO-7,都证明了BIRC5mRNA的剂量依赖抑制.
- 在蛋白质水平上,ASO-7显著抑制了生存蛋白的产生.
结论:
- 开发了针对瘤基因BIRC5.5的固体阻断ASO.
- ASO-7 是 BIRC5 mRNA 和幸存蛋白的强有力的抑制剂.
- 作为BIRC5抑制剂,ASO-7对研究和治疗开发具有前景.
更多相关视频
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
09:48Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
相关概念视频
Experimental RNAi
MicroRNAs
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
The JAK-STAT Signaling Pathway
Drugs that Stabilize Microtubules